CRA acquires bioStrategies Group, Inc.
Today CRA announced its acquisition of bioStrategies Group, Inc., a Chicago-based consulting firm focused on developing commercial strategies for healthcare...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Chris Schneider is Vice President at CRA and has more than 20 years of broad biopharma experience in a variety of commercial strategy and analytical roles on both the client and the consulting sides of the business. He brings to his engagements more than 10 years of client-side experience at both Roche and Pfizer across the finance, strategic pricing, customer development, and business development functions.
His areas of specialization have been pipeline and pre-launch commercial strategy, new product forecasting, asset/pipeline commercial evaluations, indication prioritization, lifecycle management, and market access/pricing. Chris has managed multi-phase strategy projects across a broad range of therapeutic categories, with particular focus in oncology, hematology, immunology, rare diseases, and endocrinology.
Prior to joining CRA, Chris was Partner of bioStrategies Group, a firm offering research and analysis in support of commercial strategy decisions to life science companies. Previously he worked at Roger Green and Associates and Ipsos.